Skip to main content
Log in

Long-term kidney outcomes in non-dialyzed children with Shiga-toxin Escherichia coli associated hemolytic uremic syndrome

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript



Long-term kidney outcomes of non-dialyzed children with Shiga-toxin Escherichia Coli hemolytic uremic syndrome (STEC-HUS) have been scantily studied. Therefore, we aimed to evaluate kidney outcomes and prognostic markers in these patients.


Non-dialyzed STEC-HUS patients followed for at least 5 years were included. They were grouped and compared according to kidney status at last visit: complete recovery (CR) or chronic kidney disease (CKD). Predictors of CKD evaluated at diagnosis were sex, age, leukocytes, hematocrit, hemoglobin (Hb), and serum creatinine (sCr). Peak sCr and time of follow-up were also analyzed.


A total of 122 patients (62 female, median age at diagnosis 1.6 years) with a median follow-up of 11.3 years were included. At last visit, 82 (67%) had CR, 36 (30%) had CKD stage 1, and 4 (3%) had stage 2. No patient developed CKD stage 3–5. Median time to CKD was 5 years (IQR 3.1–8.76 years). Of the 122 patients, 18% evolved to CKD in the first 5 years, increasing to 28% at 10 and 33% at 20 years of follow-up. Serum Cr at diagnosis and peak sCr were significantly higher in patients with CKD than in those with CR.


One third of non-dialyzed STEC-HUS patients evolved to CKD after a median time of 5 years. However, CKD may appear even after 15 years of CR. Serum Cr was significantly higher among patients who evolved to CKD. These data reinforce that all non-dialyzed patients should be followed until adulthood.

Graphical abstract

A higher resolution version of the Graphical abstract is available as Supplementary information

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others


  1. Siegler RL, Milligan MK, Burningham TH, Christofferson RD, Chang SY, Jorde LB (1991) Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome. J Pediatr 118:195–200.

    Article  CAS  PubMed  Google Scholar 

  2. Spizzirri FD, Rahman RC, Bibiloni N, Ruscasso JD, Amoreo OR (1997) Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. Pediatr Nephrol 11:156–160.

    Article  CAS  PubMed  Google Scholar 

  3. Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS (2013) Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28:2097–2105.

    Article  PubMed  Google Scholar 

  4. Oakes RS, Kirkham JK, Nelson RD, Siegler RL (2008) Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 23:1303–1308.

    Article  PubMed  Google Scholar 

  5. Cobeñas CJ, Alconcher LF, Spizzirri AP, Rahman RC (2007) Long-term follow-up of Argentinean patients with hemolytic uremic syndrome who had not undergone dialysis. Pediatr Nephrol 22:1343–1347.

    Article  PubMed  Google Scholar 

  6. Balestracci A, Meni Battaglia L, Toledo I, Martin SM, Puyol I, Beaudoin L, Robledo NL (2021) Diagnostic sensitivity of extended renal and hematologic criteria to define hemolytic uremic syndrome. Arch Argent Pediatr 119:238–244.

    Article  PubMed  Google Scholar 

  7. Coccia P, Ramírez F, Suárez A, Alconcher L, Balestracci A et al (2021) Acute peritoneal dialysis, complications and outcomes in 389 children with STEC-HUS: a multicenter experience. Pediatr Nephrol 36:1597–1606.

    Article  PubMed  Google Scholar 

  8. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263.

    Article  CAS  PubMed  Google Scholar 

  9. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS, National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (2003) National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 111:1416–1421.

    Article  PubMed  Google Scholar 

  10. Cubillos CMP, Del Salas P, Zambrano PO (2015) Microalbuminuria in pediatric patients diagnosed with hemolytic uremic syndrome. Rev Chil Pediatr 86:92–96.

    Article  Google Scholar 

  11. Flynn JT, Kaelber DC, Baker-Smith CM, Subcommittee on screening and management of high blood pressure in children et al (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140:e20171904.

    Article  PubMed  Google Scholar 

  12. KDIGO CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150.

  13. Pundzienė B, Dobilienė D, Čerkauskienė R, Mitkienė R, Medzevičienė A, Darškuvienė E, Jankauskienė A (2015) Long-term follow-up of children with typical hemolytic uremic syndrome. Medicina 51:146–151.

    Article  PubMed  Google Scholar 

  14. Monet-Didailler C, Godron-Dubrasquet A, Madden I, Delmas Y, Llanas B, Harambat J (2019) Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort. Pediatr Nephrol 34:657–662.

    Article  PubMed  Google Scholar 

  15. Repetto HA (2005) Long-term course and mechanisms of progression of renal disease in hemolytic uremic syndrome. Kidney Int 97:S102–S106.

    Article  Google Scholar 

  16. Lou-Meda R, Oakes RS, Gilstrap JN, Williams CG, Siegler RL (2007) Prognostic significance of microalbuminuria in postdiarrheal hemolytic uremic syndrome. Pediatr Nephrol 22:117–120.

    Article  PubMed  Google Scholar 

  17. Small G, Watson AR, Evans JH, Gallagher J (1999) Hemolytic uremic syndrome: defining the need for long-term follow-up. Clin Nephrol 52:352–356

    CAS  PubMed  Google Scholar 

  18. Van Dyck M, Proesmans W (2004) Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol 19:688–690.

    Article  PubMed  Google Scholar 

  19. Caletti MG, Missoni M, Vezzani C, Grignoli M, Piantanida JJ, Repetto HA, Exeni R, Rasse SM (2011) Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy. Pediatr Nephrol 26:1247–1254.

    Article  PubMed  Google Scholar 

  20. Caletti MG, Balestracci A, Missoni M, Vezzani C (2013) Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome. Pediatr Nephrol 28:745–750.

    Article  PubMed  Google Scholar 

  21. Ardissino G, Daccò V, Testa S, Civitillo CF, Tel F, Possenti I, Belingheri M, Castorina P, Bolsa-Ghiringhelli N, Tedeschi S, Paglialonga F, Salardi S, Consonni D, Zoia E, Salice P, Chidini G (2015) Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome. Pediatr Nephrol 30:345–352.

    Article  PubMed  Google Scholar 

Download references


The authors gratefully acknowledge the assistance of Alejandro Balestracci, MD PhD, in the preparation of this manuscript and María Eugenia Elorza, PhD in Economics, and Fernanda Villarreal, PhD in Economics, for the statistical analysis done at Universidad Nacional del Sur.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Laura F. Alconcher.

Ethics declarations

This was an observational, retrospective study. The Review Boards and Ethics Committees approved this study. The requirement to obtain informed consent was waived by the institutional review boards.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Below is the link to the electronic supplementary material.

Graphical Abstract (PPTX 96 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alconcher, L.F., Lucarelli, L.I. & Bronfen, S. Long-term kidney outcomes in non-dialyzed children with Shiga-toxin Escherichia coli associated hemolytic uremic syndrome. Pediatr Nephrol 38, 2131–2136 (2023).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: